Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
John F. Seymour(The Royal Melbourne Hospital), Arnon P. Kater(Amsterdam University Medical Centers), Thomas J. Kipps(University of California San Diego), Marco Montillo(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Yan Li(Hebei Medical University), Rod Humerickhouse(Abbott Fund), Carolyn Owen(University of Calgary), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), Sarit Assouline(Jewish General Hospital), Michelle Boyer(Amgen (United States)), James D’Rozario(Australian National University), Javier de la Serna(Hospital Universitario 12 De Octubre), Tadeusz Robak(Medical University of Lodz), Barbara Eichhorst(University of Cologne), Kathryn Humphrey(Roche (United Kingdom)), Mehrdad Mobasher(University Hospital Cologne), Elizabeth A. Punnoose(University Hospital Cologne), Ulrich Jaeger(Medical University of Vienna), Guillaume Cartron(Hôpital Saint Eloi)
Cited by 907
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k